| 2025-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | | 2025 |
| 2025-12-31 | Intuitive Surgical, Inc. | $18,800 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-12-31 | Intuitive Surgical, Inc. | $5,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-12-31 | Intuitive Surgical, Inc. | $4,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-12-31 | Intuitive Surgical, Inc. | $2,500 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-12-19 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Research payment | Cash or cash equivalent | | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), | 2025 |
| 2025-12-04 | Gilead Sciences, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Trodelvy Drug, ONC | | 2025 |
| 2025-12-04 | Janssen Biotech, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ERLEADA Drug, Oncology | | 2025 |
| 2025-11-25 | BeOne Medicines USA, Inc. | $800 | Grant | Cash or cash equivalent | BRUKINSA Drug, Oncology | | 2025 |
| 2025-11-17 | Janssen Biotech, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | RYBREVANT Drug, Oncology | | 2025 |
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-10-14 | Ipsen Biopharmaceuticals, Inc | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Onivyde Drug, Oncology | | 2025 |
| 2025-10-07 | Incyte Corporation | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-09-30 | Intuitive Surgical, Inc. | $18,800 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-09-30 | Intuitive Surgical, Inc. | $5,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-09-30 | Intuitive Surgical, Inc. | $4,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-09-30 | Intuitive Surgical, Inc. | $2,500 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-09-29 | Kite Pharma, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Yescarta Drug, CELLT | | 2025 |
| 2025-09-15 | ABBVIE INC. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | | 2025 |
| 2025-09-09 | Amgen Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-08-25 | Takeda Pharmaceuticals U.S.A., Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | | 2025 |
| 2025-08-22 | MED-EL Corporation | $9,090 | Long term medical supply or device loan | In-kind items and services | Mi1250 SYNCHRONY 2 FLEXsoft Device, Cochlear Implant | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $73 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, TLTS, 2.0 X 7 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $73 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, TLTS, 2.3 X 11 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $73 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, TLTS, 2.3 X 9 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $73 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, TLTS, 2.0 X 19 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $73 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, TLTS, 2.0 X 13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $73 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, TLTS, 2.0 X 5 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $67 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, MMF, DRILL FREE, 2.0 X 8 MM THD, TTL=12 MM, STAINLESS STEEL ASTM F138, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $67 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, MMF, DRILL FREE, 2.0 X 8 MM THD, TTL=12 MM, STAINLESS STEEL ASTM F138, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $67 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, MMF, DRILL FREE, 2.0 X 12 MM THD, TTL=16 MM, STAINLESS STEEL ASTM F138, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, EMERGENCY, 2.5 X 9 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 5 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 15 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 9 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 9 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 15 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 5 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 19 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 17 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, EMERGENCY, 2.5 X 9 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 7 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, EMERGENCY, 2.5 X 13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 11 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 11 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $30 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.3 X 7 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $25 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, DRILL FREE, 2.0 X 7 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $25 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.0 X 15 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $25 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.0 X 13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $25 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.0 X 9 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $25 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.0 X 19 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $25 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.0 X 11 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $25 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, 2.0 X 17 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-18 | KLS-Martin L.P. | $25 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE CMF, SCREW, MAXDRIVE, DRILL FREE, 2.0 X 5 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis | | 2025 |
| 2025-07-02 | Eisai Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lenvima Drug, Oncology | | 2025 |
| 2025-07-01 | Takeda Pharmaceuticals U.S.A., Inc. | $135 | Research payment | Cash or cash equivalent | | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), | 2025 |
| 2025-06-30 | Intuitive Surgical, Inc. | $18,800 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-06-30 | Intuitive Surgical, Inc. | $5,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-06-30 | Intuitive Surgical, Inc. | $4,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-06-30 | Intuitive Surgical, Inc. | $2,500 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-06-25 | TAIHO ONCOLOGY, INC. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LONSURF Drug, Oncology | | 2025 |
| 2025-06-24 | Astellas Pharma US Inc | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cresemba Drug, Infectious Diseases | | 2025 |
| 2025-06-24 | Merck Sharp & Dohme LLC | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | | 2025 |
| 2025-06-19 | Immunocore Limited | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | KIMMTRAK Drug, Oncology | | 2025 |
| 2025-06-18 | Kite Pharma, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Yescarta Drug, CELLT | | 2025 |
| 2025-06-17 | Janssen Biotech, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DARZALEX Biological, Oncology | | 2025 |
| 2025-06-06 | E.R. Squibb & Sons, L.L.C. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | OPDIVO Biological, Oncology | | 2025 |
| 2025-06-04 | Takeda Pharmaceuticals U.S.A., Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ICLUSIG Drug, ONCOLOGY | | 2025 |
| 2025-06-02 | PFIZER INC. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TUKYSA Drug, ONCOLOGY | | 2025 |
| 2025-06-01 | Takeda Pharmaceuticals U.S.A., Inc. | $1,312 | Research payment | Cash or cash equivalent | | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), | 2025 |
| 2025-05-28 | PFIZER INC. | $800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | PADCEV Biological, ONCOLOGY | | 2025 |
| 2025-05-15 | Takeda Pharmaceuticals U.S.A., Inc. | $6,000 | Research payment | Cash or cash equivalent | | TAK-007 in Refractory Lupus Nephritis | 2025 |
| 2025-04-01 | Takeda Pharmaceuticals U.S.A., Inc. | $1,312 | Research payment | Cash or cash equivalent | | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), | 2025 |
| 2025-04-01 | Takeda Pharmaceuticals U.S.A., Inc. | $159 | Research payment | Cash or cash equivalent | | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), | 2025 |
| 2025-04-01 | Takeda Pharmaceuticals U.S.A., Inc. | $135 | Research payment | Cash or cash equivalent | | A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), | 2025 |
| 2025-03-31 | Intuitive Surgical, Inc. | $18,800 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-03-31 | Intuitive Surgical, Inc. | $5,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-03-31 | Intuitive Surgical, Inc. | $4,000 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-03-31 | Intuitive Surgical, Inc. | $2,500 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | | 2025 |
| 2025-03-20 | Astellas Pharma US Inc | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cresemba Drug, Infectious Diseases | | 2025 |
| 2025-03-20 | Merck Sharp & Dohme LLC | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | | 2025 |
| 2025-03-19 | Kite Pharma, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Yescarta Drug, CELLT | | 2025 |
| 2025-03-17 | ABBVIE INC. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | | 2025 |
| 2025-03-14 | Janssen Biotech, Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ERLEADA Drug, Oncology | | 2025 |
| 2025-03-11 | Incyte Corporation | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-03-07 | JAZZ PHARMACEUTICALS INC. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ZIIHERA Drug, HEMATOLOGY/ONCOLOGY | | 2025 |
| 2025-03-05 | Eisai Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lenvima Drug, Oncology | | 2025 |
| 2025-03-04 | E.R. Squibb & Sons, L.L.C. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | REBLOZYL Biological, Hematology | | 2025 |
| 2025-01-22 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Research payment | Cash or cash equivalent | | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2025 |
| 2025-01-22 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Research payment | Cash or cash equivalent | | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2025 |
| 2025-01-22 | Takeda Pharmaceuticals U.S.A., Inc. | $550 | Research payment | Cash or cash equivalent | | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 W | 2025 |
| 2025-01-15 | Eisai Inc. | $800 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Lenvima Drug, Oncology | | 2025 |
| 2025-01-09 | Bayer Healthcare Pharmaceuticals Inc. | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Nubeqa Drug, Oncology | | 2025 |
Comments